Observational studyDermatology (Basel, Switzerland)2026
Clinical and Immunological Outcomes of Rituximab Therapy in Pemphigus: A Prospective Observational Study.
Observational study in Dermatology (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Pemphigus is a rare group of autoimmune blistering diseases, most often mediated by IgG autoantibodies but occasionally involving IgA or other immunoglobulin classes, characterized by the loss of epidermal cell adhesion due to desmoglein-targeted autoantibodies. Rituximab, an anti-CD20 monoclonal antibody, has emerged as a novel and effective treatment, offering targeted B-cell depletion.
methodsA prospective observational study was conducted on 51 patients with confirmed pemphigus. Patients received either the RA protocol (1 g rituximab 2 weeks apart) or the lymphoma protocol (375 mg/m2 weekly for 4 weeks). Disease stages were defined according to the international consensus on pemphigus [Murrell et al., J Am Acad Dermatol. 2008;58(6):1043-6]. Desmoglein 1 and 3 levels were measured using ELISA at baseline and at 6 months. Patients receiving DCP therapy were analyzed separately but excluded from primary rituximab remission analysis. Clinical remission, relapse, and adverse events were recorded.
resultsMost patients (70.59%) were diagnosed with pemphigus vulgaris, and 72.55% achieved complete remission. Mean Dsg1 levels significantly reduced from 211.96 ± 109.10 to 10.95 ± 25.43 and Dsg3 from 206.08 ± 105.11 to 17.69 ± 47.79 (p < 0.001). Patients receiving the RA protocol demonstrated a slightly greater reduction in Dsg3 titers compared to the lymphoma group, though not statistically significant. Recalcitrant disease was noted in 21.57% of cases. The low RA protocol was the most commonly used (70.59%). Adverse events were minimal and included mild infusion reactions. Mortality was reported in 5.88% of cases.
conclusionRituximab therapy demonstrates robust clinical and immunological efficacy in pemphigus, with substantial reductions in Dsg1 and Dsg3 antibody levels and high remission rates. Its use, particularly with the low RA protocol, offers a safer and more effective alternative to conventional immunosuppressive regimens. Patients on DCP therapy had slower antibody decline and greater treatment toxicity compared to rituximab, reaffirming rituximab's superiority. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.